JUSH on OTC
Jushi Holdings Inc.
Canadian medicinal chemicals and botanical products company based in Boca Raton1
In its 2026 annual report the company says: “We are a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing operations in both medical and adult-use markets. We are focused on building a diverse portfolio of cannabis assets through opportunistic investments and pursuing application opportunities in attractive limited license jurisdictions.”4 Its shares trade on OTC under the symbol JUSH.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with biote Corp., Glass House Brands Inc. or MARIMED INC., or pick any stock.
- TickerJUSH on OTC1
- IndustryMedicinal Chemicals & Botanical Products1
- HeadquartersBoca Raton, Florida1
- Incorporated inBritish Columbia, Canada2
- Business address301 Yamato Road, Suite 3250, Boca Raton, Fl 334312
- Filer category, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing operations in both medical and adult-use markets. We are focused on building a diverse portfolio of cannabis assets through opportunistic investments and pursuing application opportunities in attractive limited license jurisdictions. We have targeted assets in highly populated, limited license medical markets that are on a trajectory toward adult-use legalization, including Pennsylvania, markets that are in the process of transitioning to adult use, namely Virginia, and limited license, large adult-use markets, such as Illinois, Massachusetts, Nevada, New Jersey and Ohio, and certain municipalities of California.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
43.4%Gross margin5
1.8%Operating margin5
-26.1%Net margin5
2.1%Revenue growth, 20255
$1.6MFree cash flow5
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Retail cannabis [member] brought in 90% of the revenue Jushi Holdings Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Retail cannabis [member] | $239.4M | $227.9M | $235.5M |
| Wholesale Cannabis | $30.1M | $29.6M | $27.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue51¢$148.9M
- Selling, general and admin37¢$109.1M
- Income tax12¢$35.0M
Out of $262.9M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending91¢$16.1M
- Kept or used elsewhere9¢$1.6M
Out of $17.7M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| REVENUE, NET | $262.9M | $257.5M | $269.4M |
| COST OF GOODS SOLD | -$148.9M | -$139.2M | -$153.2M |
| GROSS PROFIT | $114.0M | $118.3M | $116.2M |
| Selling, general and administrative | $109.1M | $107.0M | $110.5M |
| Asset impairments | $0 | $432.0K | $8.6M |
| Total operating expenses | $109.1M | $107.4M | $119.0M |
| INCOME (LOSS) FROM OPERATIONS | $4.9M | $10.9M | -$2.8M |
| Interest expense, net | -$40.8M | -$37.4M | -$37.0M |
| Fair value gain (loss) on derivatives | -$5.1M | $6.3M | $9.6M |
| Other, net | $7.5M | $3.1M | -$3.1M |
| Total other income (expense), net | -$38.5M | -$28.0M | -$30.5M |
| LOSS BEFORE INCOME TAX | -$33.6M | -$17.1M | -$33.3M |
| Income tax expense | -$35.0M | -$31.6M | -$31.8M |
| NET LOSS | -$68.6M | -$48.8M | -$65.1M |
| LOSS PER SHARE - BASIC (in dollars per share) | -$0.35 | -$0.25 | -$0.33 |
| LOSS PER SHARE - DILUTED (in dollars per share) | -$0.35 | -$0.25 | -$0.33 |
| Weighted average shares outstanding - basic (in shares) | 195.2M shares | 195.2M shares | 194.8M shares |
| Weighted average shares outstanding - diluted (in shares) | 195.2M shares | 195.2M shares | 194.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $24.0M | $19.5M | ||
| Accounts receivable, net | $2.8M | $1.5M | ||
| Inventories, net | $34.6M | $36.1M | ||
| Prepaid expenses and other current assets | $6.9M | $15.0M | ||
| Total current assets | $68.3M | $72.2M | ||
| Property, plant and equipment, net | $143.3M | $144.1M | ||
| Right-of-use assets - finance leases | $57.7M | $60.6M | ||
| Other intangible assets, net | $92.2M | $100.5M | ||
| Goodwill | $30.9M | $30.9M | ||
| Other non-current assets | $27.8M | $30.3M | ||
| Restricted cash - non-current | $2.1M | $1.8M | ||
| Total non-current assets | $354.0M | $368.2M | ||
| Total assets | $422.3M | $440.3M | ||
| Accounts payable | $22.3M | $21.5M | ||
| Accrued expenses and other current liabilities | $25.5M | $32.8M | ||
| Income tax payable | $265.0K | $2.3M | ||
| Debt, net - current portion (including related party principal amounts of $0 and $800 as of December 31, 2025 and 2024, respectively) | $6.6M | $2.8M | ||
| Finance lease obligations - current | $11.1M | $9.6M | ||
| Derivative liabilities - current | $296.0K | $0 | ||
| Total current liabilities | $66.2M | $68.9M | ||
| Debt, net - non-current (including related party principal amounts of $41,109 and $35,296 as of December 31, 2025 and 2024, respectively) | $199.2M | $183.4M | ||
| Finance lease obligations - non-current | $53.5M | $52.7M | ||
| Derivative liabilities - non-current | $8.3M | $3.1M | ||
| Unrecognized tax benefits (including interest and penalties of $38,342 and $27,839 as of December 31, 2025 and 2024, respectively) | $177.2M | $143.7M | ||
| Other liabilities - non-current | $33.2M | $38.7M | ||
| Total non-current liabilities | $471.5M | $421.7M | ||
| Total liabilities | $537.7M | $490.6M | ||
| Common stock, no par value; authorized shares - unlimited; issued and outstanding shares - 199,696,597 and 196,696,597 Subordinate Voting Shares as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Paid-in capital | $511.9M | $508.4M | ||
| Accumulated deficit | -$627.2M | -$558.6M | ||
| Total Jushi shareholders' equity (deficit) | -$115.3M | -$50.2M | ||
| Non-controlling interests | $0 | $0 | ||
| Total deficit | -$115.3M | -$50.2M | -$7.6M | $45.9M |
| Total liabilities and equity (deficit) | $422.3M | $440.3M | ||
| Uncertain tax liability, interest and penalties | $38.3M | $27.8M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $24.0M | $19.5M | ||
| Accounts receivable, net | $2.8M | $1.5M | ||
| Inventories, net | $34.6M | $36.1M | ||
| Prepaid expenses and other current assets | $6.9M | $15.0M | ||
| Total current assets | $68.3M | $72.2M | ||
| Property, plant and equipment, net | $143.3M | $144.1M | ||
| Right-of-use assets - finance leases | $57.7M | $60.6M | ||
| Other intangible assets, net | $92.2M | $100.5M | ||
| Goodwill | $30.9M | $30.9M | ||
| Other non-current assets | $27.8M | $30.3M | ||
| Restricted cash - non-current | $2.1M | $1.8M | ||
| Total non-current assets | $354.0M | $368.2M | ||
| Total assets | $422.3M | $440.3M | ||
| Accounts payable | $22.3M | $21.5M | ||
| Accrued expenses and other current liabilities | $25.5M | $32.8M | ||
| Income tax payable | $265.0K | $2.3M | ||
| Debt, net - current portion (including related party principal amounts of $0 and $800 as of December 31, 2025 and 2024, respectively) | $6.6M | $2.8M | ||
| Finance lease obligations - current | $11.1M | $9.6M | ||
| Derivative liabilities - current | $296.0K | $0 | ||
| Total current liabilities | $66.2M | $68.9M | ||
| Debt, net - non-current (including related party principal amounts of $41,109 and $35,296 as of December 31, 2025 and 2024, respectively) | $199.2M | $183.4M | ||
| Finance lease obligations - non-current | $53.5M | $52.7M | ||
| Derivative liabilities - non-current | $8.3M | $3.1M | ||
| Unrecognized tax benefits (including interest and penalties of $38,342 and $27,839 as of December 31, 2025 and 2024, respectively) | $177.2M | $143.7M | ||
| Other liabilities - non-current | $33.2M | $38.7M | ||
| Total non-current liabilities | $471.5M | $421.7M | ||
| Total liabilities | $537.7M | $490.6M | ||
| Common stock, no par value; authorized shares - unlimited; issued and outstanding shares - 199,696,597 and 196,696,597 Subordinate Voting Shares as of December 31, 2025 and 2024, respectively | $0 | $0 | ||
| Paid-in capital | $511.9M | $508.4M | ||
| Accumulated deficit | -$627.2M | -$558.6M | ||
| Total Jushi shareholders' equity (deficit) | -$115.3M | -$50.2M | ||
| Non-controlling interests | $0 | $0 | ||
| Total deficit | -$115.3M | -$50.2M | -$7.6M | $45.9M |
| Total liabilities and equity (deficit) | $422.3M | $440.3M | ||
| Uncertain tax liability, interest and penalties | $38.3M | $27.8M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$68.6M | -$48.8M | -$65.1M |
| Depreciation and amortization, including amounts in cost of goods sold | $31.0M | $29.9M | $26.6M |
| Share-based compensation | $2.1M | $4.2M | $8.1M |
| Fair value changes in derivatives | $5.1M | -$6.3M | -$9.6M |
| Non-cash interest expense, including amortization of deferred financing costs | $9.8M | $7.0M | $6.5M |
| Deferred income taxes and uncertain tax positions | $34.1M | $28.9M | $25.9M |
| Loss on debt extinguishment | $0 | $362.0K | $0 |
| Asset impairments | $0 | $432.0K | $8.6M |
| Gain on asset disposals | -$2.4M | -$732.0K | -$1.6M |
| Gain on deconsolidation of Jushi Europe | $0 | -$1.9M | $0 |
| Other non-cash items, net | $3.9M | $2.2M | $8.9M |
| Accounts receivable | -$1.1M | $1.9M | -$2.4M |
| Inventory | $1.8M | -$4.0M | -$4.7M |
| Prepaid expenses and other current and non-current assets | $1.1M | -$1.5M | $404.0K |
| Accounts payable, accrued expenses and other current liabilities | $893.0K | $9.8M | -$4.8M |
| Net cash flows provided by (used in) operating activities | $17.7M | $21.6M | -$3.3M |
| Payments for property, plant and equipment | -$16.1M | -$4.7M | -$10.7M |
| Investments in intangible assets | -$1.2M | $0 | $0 |
| Proceeds from sale of assets | $4.1M | $2.8M | $4.4M |
| Payments for investments, net of cash of $218 | $0 | -$5.2M | $0 |
| Net cash flows used in investing activities | -$13.2M | -$7.1M | -$6.4M |
| Proceeds from exercise of options | $0 | $39.0K | $0 |
| Payments of promissory notes | -$175.0K | -$6.3M | $0 |
| Payments of acquisition related credit facility | $0 | -$60.1M | -$4.9M |
| Payments of finance leases | -$2.2M | -$2.1M | -$3.5M |
| Payments of loan financing costs | -$11.0K | -$2.7M | -$250.0K |
| Proceeds from other financing activities | $0 | $1.6M | $3.9M |
| Payments of other financing activities | -$1.9M | -$2.0M | -$3.0M |
| Net cash flows provided by (used in) financing activities | $767.0K | -$24.5M | $13.9M |
| NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | $5.3M | -$10.0M | $4.2M |
| Cash paid for interest (excluding capitalized interest) | $30.2M | $30.1M | $29.4M |
| Cash paid (received) for income taxes, net | $2.5M | -$4.4M | $2.8M |
| Capital expenditures | $2.4M | $2.9M | $1.5M |
| Right-of-use assets from finance lease liabilities | $3.5M | $2.0M | $681.0K |
| Issuance of second lien notes for settlement of accrued bonus | $0 | $1.4M | $1.9M |
| Issuance of promissory notes for acquisitions | $5.9M | $0 | $0 |
| Warrants issued for second lien notes | $1.8M | $0 | $0 |
| Financed insurance premiums | $1.5M | $0 | $0 |
| Property, plant and equipment from finance lease liabilities | $1.1M | $0 | $0 |
| Mortgage loans used for capital expenditure | $507.0K | $0 | $0 |
| Issuance of second lien notes for debt exchange | $0 | $4.8M | $0 |
| Warrants issued for debt exchange | $0 | $863.0K | $0 |
| Warrants issued for 2024 term loan | $0 | $6.8M | $0 |
| Issuance of debt to acquire non-controlling interest in Northern Cardinal | $0 | $175.0K | $0 |
| Note receivable issued for sale of business license | $0 | $300.0K | $0 |
| Payments for investments, net of cash | $218.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Jushi Holdings Inc. sits at the top of its group. 69 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Jushi Holdings Inc.
- James Cacioppo Filed SCHEDULE 13D/A on Jushi Holdings Inc., latest Sep 3, 2026 (11 filings since Sep 1, 2023)
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND Filed SCHEDULE 13G/A on Jushi Holdings Inc., latest Feb 13, 2026 (2 filings since Nov 13, 2025)
- Marex Securities Products Inc. Filed SCHEDULE 13G on Jushi Holdings Inc., latest Nov 26, 2025
- Nomura Holdings Filed SCHEDULE 13G/A on Jushi Holdings Inc., latest May 15, 2025 (3 filings since Feb 14, 2024)
- Denis J. Arsenault Filed SCHEDULE 13G/A on Jushi Holdings Inc., latest Feb 14, 2025 (2 filings since Sep 1, 2023)
- Jushi Holdings Inc. Boca Raton, Florida
- 1996 Holdings, LLC Subsidiary · Ohio, United States
- Agape Total Health Care Inc. Subsidiary · Pennsylvania, United States
- Bear Flag Assets, LLC Subsidiary · California, United States
- Beyond Hello CA, LLC Subsidiary · California, United States
- Beyond Hello IL Holdings, LLC Subsidiary · Illinois, United States
- Beyond Hello IL, LLC Subsidiary · Illinois, United States
- Beyond Hello Little Ferry, LLC Subsidiary · New Jersey, United States
- Campbell Hill Ventures, LLC Subsidiary · Ohio, United States
- CH1B OH LLC Subsidiary · Ohio, United States
- Dalitso, LLC Subsidiary · Virginia, United States
- Eagle Eye Enlightenment, Inc. Subsidiary · Delaware, United States
- Franklin Bioscience NV LLC Subsidiary · Nevada, United States
- Franklin Bioscience OH, LLC Subsidiary · Ohio, United States
- Franklin Bioscience – NE LLC Subsidiary · Pennsylvania, United States
- Franklin Bioscience – Penn LLC Subsidiary · Pennsylvania, United States
- Franklin Bioscience – SW LLC Subsidiary · Pennsylvania, United States
- GSG SBCA, Inc. Subsidiary · California, United States
- JMGT, LLC Subsidiary · Florida, United States
- JPTREH LDA Subsidiary · Portugal
- JREH, LLC Subsidiary · Delaware, United States
- JREHCA, LLC Subsidiary · California, United States
- JREHIL, LLC Subsidiary · Illinois, United States
- JREHNV, LLC Subsidiary · Nevada, United States
- JREHOH, LLC Subsidiary · Ohio, United States
- JREHPA, LLC Subsidiary · Pennsylvania, United States
- and 43 more
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Jushi Holdings Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $213.5M5 Dec 31, 2025 | $198.7M5 Dec 31, 2024 | +7.4% |
| Accumulated depreciation | $70.2M5 Dec 31, 2025 | $54.6M5 Dec 31, 2024 | +28.4% |
| Property and equipment, net | $143.3M5 Dec 31, 2025 | $144.1M5 Dec 31, 2024 | −0.5% |
| Finance-lease assets | $57.7M5 Dec 31, 2025 | $60.6M5 Dec 31, 2024 | −4.9% |
| Operating-lease assets (leased space) | $19.7M5 Dec 31, 2025 | $18.1M5 Dec 31, 2024 | +8.9% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $24.0M5 Dec 31, 2025 | $19.5M5 Dec 31, 2024 | +23.2% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $30.9M5 Dec 31, 2025 | $30.9M5 Dec 31, 2024 | 0% |
| Intangible assets, net (excluding goodwill) | $92.2M5 Dec 31, 2025 | $100.5M5 Dec 31, 2024 | −8.2% |
| Finite-lived intangibles, gross | $118.8M5 Dec 31, 2025 | $118.1M5 Dec 31, 2024 | +0.6% |
| Accumulated amortization | $26.6M5 Dec 31, 2025 | $17.6M5 Dec 31, 2024 | +51.2% |
| Finite-lived intangibles, net | $92.2M5 Dec 31, 2025 | $100.4M10 Dec 31, 2024 | −8.2% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $34.6M5 Dec 31, 2025 | $36.1M5 Dec 31, 2024 | −4.2% |
| Raw materials | $10.3M5 Dec 31, 2025 | $14.9M5 Dec 31, 2024 | −30.8% |
| Work in process | $6.9M5 Dec 31, 2025 | $4.5M5 Dec 31, 2024 | +52.6% |
| Finished goods | $17.4M5 Dec 31, 2025 | $16.7M5 Dec 31, 2024 | +4.2% |
Properties, in its own words
Our corporate headquarters are located in a leased facility in Boca Raton, Florida. The following table sets forth the Company’s principal cultivation and processing properties as of December 31, 2025.
Production Properties
The rest of Item 2
Description · Location · Leased / Owned
Columbus Facility · Columbus, OH · Leased
Lakeville Facility · Lakeville, MA · Leased
Manassas Facility · Manassas, VA · Owned
Reno Facility · Reno, NV · Leased
Scranton Facility · Scranton, PA · Leased
Sparks Facility · Sparks, NV · Leased
Toledo Facility · Toledo, OH · Owned
As of December 31, 2025, we operated forty-two cannabis dispensaries located in California (one), Illinois (five, which includes a dispensary that, as of December 31, 2025, we were marketing for sale. In January 2026, we turned over the operations of that dispensary to the buyer pursuant to a consultant management services agreement), Massachusetts (two), New Jersey (one), Nevada (three), Ohio (six, which includes one co-located medical and adult-use dispensary which we operate pursuant to a management services agreement while awaiting regulatory approval to acquire ownership, which was received in February 2026. Our seventh co-located medical and adult-use dispensary opened in January 2026), Pennsylvania (eighteen) and Virginia (six).
Most of our locations are leased from third parties and have expiration dates between 2026 and 2043. We believe that our facilities and expansion plans are adequate for our current and anticipated needs.
Item 2 of the 10-K filed Mar 31, 2026.4
Leadership
Who has led Jushi Holdings Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerJames Cacioppo Aug 12, 2022 to now11
- PresidentLouis Jon Barack May 19, 2023 to now12
- Chief financial officerMichelle O. Mosier Jan 17, 2023 to now13
- Chief financial officerLouis Jon Barack Aug 12, 2022 to Aug 12, 202214
- Chief operating officerTodd West Apr 22, 2024 to May 17, 202415
Board members and other officers (9)
- Chief Accounting ExecutiveJames Cabral Aug 12, 2022 to Aug 12, 202216
- Chief Operations OfficerLeonardo Garcia-Berg Aug 12, 2022 to Sep 2, 202217
- Chief People OfficerNichole Lee Upshaw Dec 12, 2022 to May 19, 202318
- Board memberBenjamin Cross Aug 12, 2022 to now19
- Board memberJames Cacioppo Aug 12, 2022 to now11
- Board memberMarina Hahn Aug 12, 2022 to now20
- Board memberStephen Monroe Aug 12, 2022 to now21
- Board memberBill Wafford Oct 12, 2022 to now22
- General counselTobi Lebowitz Sep 8, 2022 to Sep 17, 202423
Named in SEC Form D filings
People the company listed in its private-offering notices.
- DirectorPeter Alan Adderton named Dec 22, 202224
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 1996 Holdings, LLC Ohio3
- Agape Total Health Care Inc. Pennsylvania3
- Bear Flag Assets, LLC California3
- Beyond Hello CA, LLC California3
- Beyond Hello IL Holdings, LLC Illinois3
- Beyond Hello IL, LLC Illinois3
- Beyond Hello Little Ferry, LLC New Jersey3
- CH1B OH LLC Ohio3
- Campbell Hill Ventures, LLC Ohio3
- Dalitso, LLC Virginia3
- Eagle Eye Enlightenment, Inc. Delaware3
- Franklin Bioscience NV LLC Nevada3
- Franklin Bioscience OH, LLC Ohio3
- Franklin Bioscience – NE LLC Pennsylvania3
- Franklin Bioscience – Penn LLC Pennsylvania3
- Franklin Bioscience – SE LLC Pennsylvania3
- Franklin Bioscience – SW LLC Pennsylvania3
- GSG SBCA, Inc. California3
- JMGT, LLC Florida3
- JPTREH LDA Portugal3
- JREH, LLC Delaware3
- JREHCA, LLC California3
- JREHIL, LLC Illinois3
- JREHNV, LLC Nevada3
All 70 listed subsidiaries
- JREHOH, LLC Ohio3
- JREHPA, LLC Pennsylvania3
- JREHVA, LLC Virginia3
- Jushi Consulting, LLC Florida3
- Jushi Europe SA Switzerland3
- Jushi FL SPV, LLC Florida3
- Jushi GB Holdings, LLC California3
- Jushi IP, LLC Delaware3
- Jushi Inc Delaware3
- Jushi MA, Inc. Massachusetts3
- Jushi Mount Laurel, LLC New Jersey3
- Jushi NJ, LLC New Jersey3
- Jushi NV CLV, Inc. Nevada3
- Jushi NV, Inc. Nevada3
- Jushi Nevada Management, LLC Nevada3
- Jushi OH, LLC Ohio3
- Jushi PA, LLC Pennsylvania3
- Jushi PS Holdings, LLC California3
- Jushi Parma OH, LLC Ohio3
- Jushi RJK OH, LLC Ohio3
- Jushi SPH OH, LLC Ohio3
- Jushi VA, LLC Virginia3
- McMann, LLC Massachusetts3
- Measured Approaches 2, LLC Delaware3
- Mojave Suncup Holdings, LLC Nevada3
- Northeast Venture Holdings, LLC Pennsylvania3
- Northern Cardinal Ventures, LLC Illinois3
- Nuleaf CLV Dispensary, LLC Nevada3
- Nuleaf Clark Dispensary, LLC Nevada3
- Nuleaf Incline Dispensary, LLC Nevada3
- Nuleaf Reno Production, LLC Nevada3
- Nuleaf Sparks Cultivation, LLC Nevada3
- OhiGrow Retail, LLC Ohio3
- Ohigrow, LLC Ohio3
- Ohio Green Grow LLC Ohio3
- Organic Solutions of the Desert LLC California3
- PASPV Holdings, LLC Pennsylvania3
- PV Culver City, LLC California3
- Pennsylvania Dispensary Solutions, LLC Pennsylvania3
- Pennsylvania Medical Solutions LLC Pennsylvania3
- Production Excellence, LLC Nevada3
- RRVI OH LLC Ohio3
- SF-D Inc. Nevada3
- Sound Wellness Holdings, Inc. Delaware3
- TGS CC Ventures, LLC California3
- Valiant Enterprises, LLC Massachusetts3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Jul 28, 20268-K Results of operations25
- Jun 24, 20268-K Shareholder vote; Other events26
- May 12, 20268-K Results of operations27
- Apr 24, 20268-K Other events28
- Mar 31, 20268-K Results of operations29
- Jan 6, 20268-K Executive or director change30
- Dec 16, 20258-K Executive or director change31
- Nov 4, 20258-K Results of operations32
- Sep 22, 20258-K Entered a material agreement; New debt or obligation; Regulation FD disclosure33
- Aug 5, 20258-K Results of operations34
- Jun 3, 20258-K Shareholder vote; Regulation FD disclosure35
- May 8, 20258-K Results of operations36
- Aug 12, 2022New chief executive James Cacioppo becomes CEO11
Calendar
When it reported results
- Jul 28, 2026Reported quarterly or annual results25
- May 12, 2026Reported quarterly or annual results27
- Mar 31, 2026Reported quarterly or annual results29
- Nov 4, 2025Reported quarterly or annual results32
- Aug 5, 2025Reported quarterly or annual results34
- May 8, 2025Reported quarterly or annual results36
- Mar 6, 2025Reported quarterly or annual results37
- Nov 7, 2024Reported quarterly or annual results38
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
243 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 51 major events, 85 insider forms, 19 large holders, 2 private raises, 68 other. The latest 20:
- Sep 22, 20264 EDGAR
- Sep 14, 20264 EDGAR
- Sep 3, 2026SCHEDULE 13D/A EDGAR
- Sep 2, 20264 EDGAR
- Sep 2, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 2026S-8 EDGAR
- Aug 26, 20264 EDGAR
- Aug 4, 20264 EDGAR
- Aug 3, 2026EFFECT EDGAR
- Aug 3, 2026EFFECT EDGAR
- Aug 3, 20264 EDGAR
- Jul 31, 2026POS AM EDGAR
- Jul 31, 2026POS AM EDGAR
- Jul 31, 2026S-8 POS S-8 EDGAR
- Jul 31, 20268-K12G3 EDGAR
- Jul 28, 202610-Q EDGAR
- Jul 28, 20268-K EDGAR
- Jun 24, 20268-K EDGAR
The 243 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
21 open-market trades by officers, directors and large owners since October 2021: 21 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Cacioppo JamesChief Executive Officer | Buy | 20 | $0.51 | $10 | Form 4 |
| Sep 8, 2026 | Arsenault Denis J.10% owner | Buy | 15,100 | $0.62 | $9.4K | Form 4 |
| Sep 3, 2026 | Arsenault Denis J.10% owner | Buy | 118,034 | $0.59 | $69.6K | Form 4 |
| Sep 1, 2026 | Cacioppo JamesChief Executive Officer | Buy | 248,000 | $0.52 | $129.0K | Form 4 |
| Aug 31, 2026 | Cacioppo JamesChief Executive Officer | Buy | 71,686 | $0.51 | $36.6K | Form 4 |
| Aug 31, 2026 | Barack Louis JonPresident | Buy | 15,000 | $0.52 | $7.8K | Form 4 |
| Aug 27, 2026 | Cacioppo JamesChief Executive Officer | Buy | 500,000 | $0.49 | $245.0K | Form 4 |
| Aug 27, 2026 | Barack Louis JonPresident | Buy | 30,000 | $0.50 | $15.0K | Form 4 |
| Aug 26, 2026 | Cacioppo JamesChief Executive Officer | Buy | 494,000 | $0.50 | $247.0K | Form 4 |
| Aug 25, 2026 | Cacioppo JamesChief Executive Officer | Buy | 322,000 | $0.49 | $157.8K | Form 4 |
| Aug 24, 2026 | Cacioppo JamesChief Executive Officer | Buy | 384,112 | $0.48 | $184.4K | Form 4 |
| Aug 4, 2026 | Barack Louis JonPresident | Buy | 10,000 | $0.43 | $4.3K | Form 4 |
| Aug 3, 2026 | Barack Louis JonPresident | Buy | 10,000 | $0.44 | $4.4K | Form 4 |
| Jul 31, 2026 | Barack Louis JonPresident | Buy | 6,400 | $0.42 | $2.7K | Form 4 |
| Jul 30, 2026 | Barack Louis JonPresident | Buy | 35,600 | $0.40 | $14.1K | Form 4 |
| Jun 15, 2026 | MOSIER MICHELLE OChief Financial Officer | Buy | 22,000 | $0.49 | $10.8K | Form 4 |
| Jun 12, 2026 | MOSIER MICHELLE OChief Financial Officer | Buy | 3,500 | $0.49 | $1.7K | Form 4 |
| Nov 14, 2024 | MOSIER MICHELLE OChief Financial Officer | Buy | 21,500 | $0.41 | $8.8K | Form 4 |
| Nov 13, 2024 | MOSIER MICHELLE OChief Financial Officer | Buy | 3,666 | $0.35 | $1.3K | Form 4 |
| Sep 12, 2023 | MOSIER MICHELLE OChief Financial Officer | Buy | 30,567 | $0.70 | $21.4K | Form 4 |
All 21 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- James CacioppoSCHEDULE 13D/A, 11 filings Sep 1, 2023 to Sep 3, 202639
- HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUNDSCHEDULE 13G/A, 2 filings Nov 13, 2025 to Feb 13, 202640
- Marex Securities Products Inc.SCHEDULE 13G, 1 filing Nov 26, 202541
- Nomura HoldingsSCHEDULE 13G/A, 3 filings Feb 14, 2024 to May 15, 202542
- Denis J. ArsenaultSCHEDULE 13G/A, 2 filings Sep 1, 2023 to Feb 14, 202543
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | James CacioppoChief Executive Officer | 63 | $1.1M | $2.9M44 |
| 2025 | Louis Jonathan BarackPresident, Chief Revenue Officer and Corporate Secretary | 49 | $450.0K | $1.0M44 |
| 2025 | Michelle MosierChief Financial Officer and Chief Accounting Officer | 60 | $425.0K | $769.6K44 |
| 2024 | James CacioppoChief Executive Officer | 63 | $850.0K | $3.6M44 |
| 2024 | Louis Jonathan BarackPresident, Chief Revenue Officer and Corporate Secretary | 49 | $414.6K | $925.2K44 |
| 2024 | Michelle MosierChief Financial Officer and Chief Accounting Officer | 60 | $414.6K | $710.2K44 |
Money raised
Private offerings the company reported to the SEC on Form D.
SEC filer profile
How Jushi Holdings Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARJushi Holdings Inc.1
- CIK0001909747
- Employer ID (EIN)98-15470614
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inBritish Columbia4
- Fiscal year endsDecember 311
- Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address301 Yamato Road, Suite 3250, Boca Raton, FL 334311
- Phone56161791001
- Shares outstanding199,698,263 as of Jul 21, 20269
- Public float$59.4M as of Jun 30, 20254
- AuditorMacias Gini & O’Connell LLP, Irvine, California PCAOB ID 324; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceMay 16, 20221
- Filings243 in all: 4 (69), 8-K (50), 3 (14), 424B3 (14), 10-Q (13), UPLOAD (8), CORRESP (7), EFFECT (6)1
All 38 form types
DEFA14A (5), SC 13D/A (5), SCHEDULE 13D/A (5), 10-K (4), ARS (4), DEF 14A (4), POS AM (3), SCHEDULE 13G/A (3), D (2), DRSLTR (2), NT 10-K (2), S-3 (2), S-8 (2), SC 13G (2), SCHEDULE 13G (2), 10-K/A (1), 3/A (1), 4/A (1), 8-A12G (1), 8-K/A (1), 8-K12G3 (1), DRS (1), DRS/A (1), NT 10-Q (1), PRE 14A (1), S-1 (1), S-1/A (1), S-8 POS (1), SC 13D (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Mar 31, 2026
Quarterly report (10-Q) Jul 28, 2026
Proxy statement (DEF 14A) May 11, 2026
Latest 8-K (8-K) Jul 28, 2026
Risk factors and legal proceedings
The risks Jushi Holdings Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 57 risks under these headings, as written.4
- Risks Related to Our Business and Industry
- Risks Related to the Regulatory Environment
- Risks Related to Owning Jushi’s Subordinate Voting Shares
- The cannabis industry is relatively new.
- We face risks due to industry immaturity and limited comparable, competitive or established industry best practices.
- Our ability to grow our medical and adult-use cannabis product offerings and dispensary services may be limited.
- We may acquire other companies or technologies.
- If we cannot manage our growth, it could have a material adverse effect on our business, financial condition and results of operations.
- We have incurred losses and negative cash flow from operations in the past, and we expect to incur significant ongoing costs and obligations related to our investments in infrastructure, growth, regulatory compliance and operations and may not be able to sustain profitability.
- The market for the Subordinate Voting Shares may be limited for holders of our securities who live in the U.S.
- We expect to be subject to taxation in both Canada and the U.S., which could have a material adverse effect on our financial condition and results of operations.
- We are a holding company and our ability to pay dividends or make other distributions to shareholders may be limited.
The other 48 risks
- We face increasing competition that may materially and adversely affect our business, financial condition and results of operations.
- We may not be able to accurately forecast our operating results and plan our operations due to uncertainties in the cannabis industry.
- We are subject to risks related to growing an agricultural product.
- We are highly dependent on certain key personnel.
- We face inherent risks of liability claims related to the use of our products.
- We may become a party to litigation in the ordinary course of business.
- We may be unable to obtain adequate insurance coverage.
- Consumer preferences may change and our products may no longer be appealing to consumers.
- Our medical marijuana business may be impacted by consumer perception of the cannabis industry, which we cannot control or predict.
- Product recalls could result in a material and adverse impact on our business, financial condition and results of operations.
- We are subject to security risks related to our products as well as our information and technology systems.
- We face exposure to fraudulent or illegal activity by employees, contractors, consultants and agents, which may subject us to investigations and actions.
- Our reputation and ability to do business may be negatively impacted by the improper conduct of our business partners, employees or agents.
- We have in the past and may in the future experience threats and breaches to our data and information technology systems, including malicious software codes, viruses, phishing, ransomware and other cyber-attacks, that disrupt our information systems or operations, or result in the dissemination of sensitive personal or confidential information or unauthorized financial access, theft or crimes, which could result in increased costs, economic losses, exposure to significant liability, reputational harm, loss of business, and other serious negative consequences.
- We have a substantial level of indebtedness that requires us to comply with restrictions and covenants, and we may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful. The terms of our indebtedness may also impair our ability to respond to changing business and economic conditions and may seriously harm our business.
- We are subject to labor risks and a dispute with our employees or labor unions could have an adverse effect on our results of operations.
- We rely on third-party suppliers, manufacturers and contractors, and other key inputs.
- We rely on key utility services.
- Inflation could pose a risk to our business.
- Cannabis is illegal under U.S. federal law.
- The regulation of cannabis in the U.S. is uncertain.
- Government inquiries and investigations could harm our business or reputation.
- We are constrained by law in our ability to market our products in the jurisdictions in which we operate.
- Anti-Money Laundering Laws in the U.S. may limit access to funds from banks and other financial institutions.
- As a cannabis business, we are subject to certain tax provisions that have a material adverse effect on our business, financial condition and results of operations.
- We are subject to tax audits by various tax authorities in multiple jurisdictions.
- We may not be successful in defending our tax filing positions, which could adversely impact our financial condition and results of operations.
- The re-classification of cannabis or changes in U.S. controlled substance laws and regulations could have a material adverse effect on our business, financial condition and results of operations.
- Potential regulation by the FDA could have a material adverse effect on our business, financial condition and results of operations.
- We could be materially adversely impacted due to restrictions under U.S. border entry laws.
- Challenging U.S. and global economic conditions may negatively impact our business, financial condition and results of operations.
- As a cannabis company, we may be subject to heightened scrutiny in Canada and the U.S. that could materially adversely impact the liquidity of the Subordinate Voting Shares.
- We may not be able to locate and obtain the rights to operate at preferred locations.
- We may not have access to U.S. bankruptcy protections available to non-cannabis businesses.
- There is doubt regarding our ability to enforce contracts.
- We are subject to limits on our ability to own the licenses necessary to operate our business, which will adversely affect our ability to grow our business and market share in certain states.
- We may not be able to adequately protect our intellectual property.
- Our property is subject to risk of civil asset forfeiture.
- We could be subject to criminal prosecution or civil liabilities under RICO.
- Return on Subordinate Voting Shares is not guaranteed.
- Raising additional capital may cause dilution to our shareholders.
- Sales of substantial amounts of Subordinate Voting Shares by our existing shareholders in the public market may have an adverse effect on the market price of the Subordinate Voting Shares.
- The market price for the Subordinate Voting Shares has been and is likely to continue to be volatile.
- If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research about our business or our market, our share price and trading volume could decline.
- There may not be sufficient liquidity in the markets for our Subordinate Voting Shares.
- We are subject to increased costs as a result of being a U.S. and Canadian reporting company.
- We are an “emerging growth company” and a “smaller reporting company” and will be able take advantage of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our Subordinate Voting Shares less attractive to investors.
- Our internal controls over financial reporting may not be effective, and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation.
Legal proceedings
From time to time, we may become involved in litigation relating to claims arising from the ordinary course of business. For a description of our legal proceedings, refer to Claims and Litigation in Note 22 - Commitments and Contingencies in the Notes to Consolidated Financial Statements of this Annual Report on Form 10-K.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARLouis Jon Barack, President
- 13
- 14
- 15SEC EDGARTodd West, Chief operating officer
- 16
- 17
- 18
- 19SEC EDGARBenjamin Cross, Board member
- 20SEC EDGARMarina Hahn, Board member
- 21SEC EDGARStephen Monroe, Board member
- 22SEC EDGARBill Wafford, Board member
- 23SEC EDGARTobi Lebowitz, General counsel
- 24
- 25SEC EDGARResults of operations
- 26SEC EDGARShareholder vote; Other events
- 27SEC EDGARResults of operations
- 28SEC EDGAROther events
- 29SEC EDGARResults of operations
- 30SEC EDGARExecutive or director change
- 31SEC EDGARExecutive or director change
- 32SEC EDGARResults of operations
- 33
- 34SEC EDGARResults of operations
- 35
- 36SEC EDGARResults of operations
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44